A Phase 2 interventional study of Axitinib (AG-013736) and Best Supportive Care in Hepatocellular Carcinoma, sponsored by Pfizer. Completed at 77 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-01-09.
Sponsored by Pfizer · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Carcinoma, Hepatocellular by Pfizer — 2 open to participants now, 2 under way, none of them phase 3. Carcinoma, Hepatocellular · Pfizer.
Among the 12 studies in Carcinoma, Hepatocellular by Pfizer, this one is the 3rd largest by enrollment, is the only one that started in 2010, is one of 3 in phase 2, and was the 4th registered.
3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,062 are open to participants now.
Browse Carcinoma, Hepatocellular studies →2 of the 12 studies in Carcinoma, Hepatocellular by Pfizer are open now, in 12 countries. Recruiting first, the newest first:
Pfizer · Sites in United States, China, Japan and 2 more countries
Ages 18+
Seagen, a wholly owned subsidiary of Pfizer · Sites in United States, Belgium, Canada and 8 more countries
Ages 18+
By country, each count listing its studies:
Of the 737 Carcinoma, Hepatocellular studies recruiting now, 382 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 4 · Phase 3 1
First in 2002; this study’s year is marked. 1 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 224 is above the median of 54 across 2,619 interventional studies indexed under Carcinoma, Hepatocellular.
Median enrollment 113 across the 12 interventional studies. Of the 9 that completed or were terminated, 7 (78%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
1 of the studies in Carcinoma, Hepatocellular by Pfizer that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07227012PfizerSymbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body. | 2027-10-18 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies in Carcinoma, Hepatocellular by Pfizer, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The study is designed to demonstrate that axitinib plus best supportive care is superior to placebo plus best supportive care in prolonging survival in patients with advanced hepatocellular carcinoma.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in this group received axitinib + best supportive care. Participants with Child-Pugh Class A disease (score 5 or 6) were enrolled into the randomized portion at a starting axitinib dose of 5 mg BID orally. Participants with Child-Pugh Class B disease (score 7) were to begin enrollment into the randomized portion of the study following determination of the recommended axitinib starting dose in the non-randomized portion. Study treatment was administered in cycles of 4 weeks in duration
Drug: Axitinib (AG-013736) · Other: Best Supportive Care
Participants in this group received placebo + best supportive care. Treatment was administered in cycles of 4 weeks in duration. The starting dose of placebo for participants with Child Pugh Class A disease (score 5 or 6) was chosen as 5 mg BID. Participants with Child-Pugh Class B, score 7 received placebo that was determined from the non-randomized portion of the study until the recommended starting dose was determined, participants with Child-Pugh Class B, score 7, were not permitted to enter the randomized portion of the study
Drug: Placebo · Other: Best Supportive Care
Axitinib \[tablet, 1 mg, 5 mg\] will be given twice daily \[BID\] with continuous dosing; duration is approximately 3-6 months; starting dose is 5 mg BID
BSC may include medications and supportive measures deemed necessary to palliate disease related symptoms and improve quality of life.
Placebo \[tablet, 1 mg, 5 mg\] will be given twice daily \[BID\] with continuous dosing; duration is approximately 3-6 months; starting dose is 5 mg BID
BSC may include medications and supportive measures deemed necessary to palliate disease related symptoms and improve quality of life.
Overall Survival (OS) - Stratified Analysis, Randomized Portion
OS was defined as the time from the date of randomization to the date of death due to any cause. OS (in months) was calculated as (date of death - first randomization date +1)/30.4. For participants still alive at the time of the analysis, the OS time was censored on the last date they were known to be alive. All participants were followed up for survival at least every 3 months after discontinuing study treatment until at least two years after randomization of the last participant.
Time frame: From randomization until at least two years after the last participant has been randomized (up to 6 years)
Progression-Free Survival (PFS) - Stratified Analysis, Randomized Portion
PFS was defined as time from randomization to first documented objective tumor progression or to death due to any cause, whichever occurred first. PFS (in months) was calculated as (first event date - first randomization date +1)/30.4. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease \[PD\]), or from adverse event (AE) data (where the outcome was death). As per response evaluation criteria in solid tumors (RECIST) 1.1, progression was defined as greater than or equal to (\>=) 20% increase in sum of longest dimensions of target lesions or appearance of one or more new target lesions and unequivocal progression of existing non-target lesions, or appearance of 1 new non-target lesions. Participants discontinuing study treatment without documented evidence of PD were to be followed up at least every 8 weeks after discontinuing study treatment until disease progression, or initiation of another anticancer treatment.
Time frame: Every 8 weeks until disease progression/death or start of new treatment or until at least two years after the last participant has been randomized, whatever occurs first
Objective Response Rate (ORR) - Percentage of Participants With Objective Response by Stratified Analysis, Randomized Portion
ORR was defined as the percentage of participants with confirmed complete response (CR) or confirmed partial response (PR) according to the RECIST 1.1. CR was defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must decrease to normal (short axis \<10 millimetres \[mm\]). PR was defined as a 30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions.
Time frame: Every 8 weeks until at least two years after the last participant has been randomized
Time to Tumor Progression (TTP) - Stratified Analysis, Randomized Portion
TTP was defined as the time from randomization to first documentation of objective tumor progression. If tumor progression data included more than 1 date, the first date was used. TTP (in months) was calculated as (first event date - first randomization date +1)/30.4.
Time frame: Every 8 weeks until disease progression/death or start of new treatment or until at least two years after the last participant has been randomized, whatever occurs first
Duration of Response (DR) by Unstratified Analysis, Randomized Portion
DR was defined as the time from the first documentation of objective tumor response (CR or PR) that was subsequently confirmed to the first documentation of PD or to death due to any cause, whichever occurs first. If tumor progression data included more than 1 date, the first date was to be used. DR (in months) was to be calculated as (the end date for DR - first CR or PR that was subsequently confirmed +1)/30.4.
Time frame: From objective response to date of progression or death
Percentage of Participants With Overall Clinical Benefit Response (CBR) - Stratified Analysis, Randomized Portion
CBR was defined as the percentage of participants with confirmed CR or confirmed PR or a best response of stable disease \>=8 weeks according to RECIST 1.1 criteria, relative to all randomized participants who had baseline measurable disease. Confirmed responses were defined as those that persisted on repeat imaging study \>=4 weeks after the initial documentation of response. Participants who did not have on study radiographic tumor re-evaluation or who died, progressed, or dropped out for any reason prior to reaching a CR, PR, or stable disease were counted as non-responders in the assessment of CBR. A participant who initially met the criteria for a PR and then subsequently became a confirmed CR was to be assigned a best response of CR.
Time frame: From Baseline up to end of treatment
Axitinib Steady-State Pharmacokinetic (PK) Parameter - Maximum Observed Plasma Concentration (Cmax), Non-Randomized Portion
Axitinib samples were to be collected from all participants on Cycle 1 Day 15 at the following time points: pre-dose, 1, 2, 3, 4, 6 and 8 hours after axitinib dosing.
Time frame: Cycle 1 Day 15
Axitinib Steady-State PK Parameter - Area Under the Plasma Concentration Versus Time Curve From 0 to 24 Hour (AUC0-24), Non-Randomized Portion
Axitinib samples were to be collected from all participants on Cycle 1 Day 15 at the following time points: pre-dose, 1, 2, 3, 4, 6 and 8 hours after axitinib dosing. In the below table, 4 participants in Child-Pugh A and 1 participant in Child-Pugh B were not reported due to nonestimable half-life.
Time frame: Cycle 1 Day 15
Axitinib Steady-State Pharmacokinetic Parameter - Time to First Occurrence of Cmax (Tmax), Non-Randomized Portion
Axitinib samples were to be collected from all participants on Cycle 1 Day 15 at the following time points: pre-dose, 1, 2, 3, 4, 6 and 8 hours after axitinib dosing.
Time frame: Cycle 1 Day 15
Axitinib Steady-State Pharmacokinetic Parameter - Apparent Oral Clearance (CL/F), Non-Randomized Portion
Axitinib samples were to be collected from all participants on Cycle 1 Day 15 at the following time points: pre-dose, 1, 2, 3, 4, 6 and 8 hours after axitinib dosing. In the below table, 4 participants in Child-Pugh A and 1 participant in Child-Pugh B were not reported due to nonestimable half-life.
Time frame: Cycle 1 Day 15
Axitinib Steady-State Pharmacokinetic Parameter - Terminal Plasma Elimination Half-Life (t1/2), Non-Randomized Portion
Axitinib samples were to be collected from all participants on Cycle 1 Day 15 at the following time points: pre-dose, 1, 2, 3, 4, 6 and 8 hours after axitinib dosing. In the below table, 4 participants in Child-Pugh A and 1 participant in Child-Pugh B were not reported due to nonestimable half-life.
Time frame: Cycle 1 Day 15
Axitinib Steady-State Pharmacokinetic Parameter - Apparent Oral Volume of Distribution of the Drug During the Elimination Phase (Vz/F), Non-Randomized Portion
Axitinib samples were to be collected from all participants on Cycle 1 Day 15 at the following time points: pre-dose, 1, 2, 3, 4, 6 and 8 hours after axitinib dosing. The PK parameter, Vz/F has been presented in this outcome measure. In the below table, 4 participants in Child-Pugh A and 1 participant in Child-Pugh B were not reported due to nonestimable half-life.
Time frame: Cycle 1 Day 15
Concentration of Soluble Proteins at Baseline in Randomized Portion
Plasma soluble proteins interleukin-6 (IL-6), E-Selectin, interleukin-8 (IL-8), hepatocyte growth factor (HGF), matrix metalloproteinase-2 (MMP-2), stem cell factor (SCF), angiopoietin-2 (Ang-2), vascular endothelial growth factor-A (VEGF-A), vascular endothelial growth factor-C (VEGF-C), soluble vascular endothelial growth factor receptor 2 (sVEGFR2), soluble vascular endothelial growth factor receptor 3 (sVEGFR3), stromal cell-derived factor-1 (SDF1), neutrophil gelatinase-associated lipocalin (NGAL), migration inhibitory factor (MIF), c-MET, regulated upon activation normal T cell expressed and presumably secreted (RANTES), and monocyte chemotactic protein-3 (MCP-3) were only measured in randomized participants.
Time frame: Baseline
Percentage of Participants With Specific Micro-Ribonucleic Acid (miRNA) Transcript Present in Circulation in Randomized Portion
A 5 millilitres (mL) whole blood sample was collected from all randomized participants to evaluate the miRNA transcripts.
Time frame: Baseline
Functional Assessment of Cancer Therapy - Hepatobiliary Questionnaire (FACT-Hep) in Randomized Portion: Overall Between-Treatment Comparison Based on the Repeated Measures Mixed Effects Model
FACT-Hep consists of 27-item FACT-G, and 18-item Hepatobiliary Subscale. FACT-Hep questionnaire uses 5-point Likert rating scale, range '0'-not at all to '4'. FACT-Hep total score ranges from 0 to 180, where highest score represents maximum achievable quality of life. Domains of FACT-G include Physical Well-Being (PWB), Social/Family Well-Being (SWB), Emotional Well-Being (EWB) and Functional Well-Being (FWB). Hepatobiliary disease specific items include: swelling or cramps, losing weight, gastrointestinal (GI)-related questions, lack of energy, side effects, pain, fatigue, usual activities, jaundice, fevers, itching, taste of food and chills. Eight of the items (pain, back pain, stomach pain/discomfort, lack of energy, fatigue, nausea, weight loss and jaundice) make up FACT-Hepatobiliary Symptom Index (FHSI-8), and are considered to be symptoms specific to hepatobiliary cancer. Table below included mixed effect model estimated average based on all observed values/time points.
Time frame: Cycle 1 Day 1 pre-dose and before any other clinical assessments, every 4 weeks thereafter while on study, at end of study treatment/withdrawal, and follow-up and at Day 28 after last dose date
Functional Assessment of Cancer Therapy - General (FACT-G) in Randomized Portion: Overall Between-Treatment Comparison Based on the Repeated Measures Mixed Effects Model
FACT-G is core questionnaire of Functional Assessment of Chronic Illness Therapy (FACIT) measurement system to evaluate QoL in cancer population. FACT-G consisted of 27 questions grouped in 4 domains of general Health-Related QoL (HRQoL): PWB, SWB, EWB and FWB; each ranging from 0 (not at all) to 4 (very much). FACT-G ranged between 0 and 108. Since questions could be reversed coded, as appropriate, before calculating FACT-G, 0 and 108 could be considered worst and best health states. The below table included the model estimated average based on all the observed values/time points. The mixed effect model was used.
Time frame: Cycle 1 Day 1 pre-dose and before any other clinical assessments, every 4 weeks thereafter while on study, at end of study treatment/withdrawal, and follow-up and at Day 28 after last dose date
Functional Assessment of Cancer Therapy (FACT)-Hepatobiliary Symptom Index-8 (FHSI-8) in Randomized Portion: Overall Between-Treatment Comparison Based on the Repeated Measures Mixed Effects Model
The FACT-Hep includes the FACT-G and a hepatobiliary module. The hepatobiliary disease specific items include: swelling or cramps, losing weight, GI related questions, lack of energy, side effects, pain, fatigue, usual activities, jaundice, fevers, itching, taste of food and chills. Eight of the items (pain, back pain, stomach pain/discomfort, lack of energy, fatigue, nausea, weight loss, and jaundice) make up the FHSI-8, and are considered to be symptoms specific to hepatobiliary cancer. FHSI-8 total score ranges from 0 to 32 where "0" is a severely symptomatic participant and the highest score indicates an asymptomatic participant. The below table included the model estimated average based on all the observed values/time points. The mixed effect model was used.
Time frame: Cycle 1 Day 1 pre-dose and before any other clinical assessments, every 4 weeks thereafter while on study, at end of study treatment/withdrawal, and follow-up and at Day 28 after last dose date
Functional Assessment of Cancer Therapy-G (FACT-G) Subscales in Randomized Portion: Overall Between-Treatment Comparison Based on the Repeated Measures Mixed Effects Model
FACT-G is core questionnaire of Functional Assessment of Chronic Illness Therapy (FACIT) measurement system to evaluate QoL in cancer population. FACT-G consisted of 27 questions grouped in 4 domains of general HRQoL: PWB, SWB, EWB and FWB. Each of the individual subscale, except EWB has 7 items and each integer scored 0 to 4 making a maximum possible score of 28 (range 0 to 28). EWB has 6 items and each integer scored 0 to 4 making a maximum possible score of 24 (range 0 to 24). For all the 4 scales, higher values correspond to better health. The below table included the model estimated average based on all the observed values/time points. The mixed effect model was used.
Time frame: Cycle 1 Day 1 pre-dose and before any other clinical assessments, every 4 weeks thereafter while on study, at end of study treatment/withdrawal, and follow-up and at Day 28 after last dose date
Functional Assessment of Cancer Therapy - Hepatobiliary Cancer Subscale (FACT Hep-CS18) Questionnaire in Randomized Portion: Overall Between-Treatment Comparison Based on the Repeated Measures Mixed Effects Model
This subscale consists of 18 items rated on a scale from '0' - not at all to '4' - very much regarding how much each item was present in the last 7 days. FACT-Hep-CS18 total score ranges from 0 to 72. The higher score reflects better QoL or fewer symptoms. The 18 items of this scale are associated with hepatocellular carcinoma. The below table included the model estimated average based on all the observed values/time points. The mixed effect model was used.
Time frame: Cycle 1 Day 1 pre-dose and before any other clinical assessments, every 4 weeks thereafter while on study, at end of study treatment/withdrawal, and follow-up and at Day 28 after last dose date
Functional Assessment of Cancer Therapy - Hepatobiliary Cancer Trial Outcome Index (FACT Hep-TOI) Questionnaire in Randomized Portion: Overall Between-Treatment Comparison Based on the Repeated Measures Mixed Effects Model
The trial outcome index is defined to be the sum (PWB+FWB+HepCS), making it 32 items altogether. Each ranges from '0' - not at all to '4' - very much regarding how much each item was present in the last 7 days. FACT Hep -TOI total score ranges from 0 to 128, where the highest score represents a maximum achievable quality of life. The below table included the model estimated average based on all the observed values/time points. The mixed effect model was used.
Time frame: Cycle 1 Day 1 pre-dose and before any other clinical assessments, every 4 weeks thereafter while on study, at end of study treatment/withdrawal, and follow-up and at Day 28 after last dose date
Time to Deterioration (TTD) Based on the Composite Endpoint in Randomized Portion: Overall Between-Treatment Comparison Based on the Repeated Measures Mixed Effects Model
TTD analysis was performed for FHSI-8. Time to deterioration was defined as the time between date of randomization and date of the event.
Time frame: From randomization to death or tumor progression or FHSI-8 mean score decrease >=3 points, whichever comes first
EuroQoL (EQ-5D)- Health State Profile Utility Score in Randomized Portion: Overall Between-Treatment Comparison Based on the Repeated Measures Mixed Effects Model
EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state. Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state. The below table included the model estimated average based on all the observed values/time points. The mixed effect model was used.
Time frame: Cycle 1 Day 1 pre-dose and before any other clinical assessments, every 4 weeks thereafter while on study, at end of study treatment/withdrawal, and follow-up and at Day 28 after last dose date
EuroQoL Visual Analogue Scale (EQ-VAS) in Randomized Portion: Overall Between-Treatment Comparison Based on the Repeated Measures Mixed Effects Model
EQ-5D VAS in rates the participant's overall health status using values from 0 (worst imaginable) to 100 (best imaginable). The below table included the model estimated average based on all the observed values/time points. The mixed effect model was used.
Time frame: Cycle 1 Day 1 pre-dose and before any other clinical assessments, every 4 weeks thereafter while on study, at end of study treatment/withdrawal, and follow-up and at Day 28 after last dose date
Number of Participants With Dose-Limiting Toxicities (DLTs) in Non-Randomized Portion
Number of Child-Pugh Class B (score 7) participants with DLT was evaluated during Cycle 1 of treatment in the non-randomized portion of the study.
Time frame: Cycle 1 (4 weeks)
Number of Participants With Treatment-Emergent Adverse Events (AEs) in Non-Randomized Portion
An AE was an untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. Serious adverse event (SAE) was an AE resulting in any of the following outcomes: death, initial or prolonged inpatient hospitalization, life-threatening experience, persistent or significant disability/incapacity, congenital anomaly. Treatment-emergent AEs were those with initial onset or that worsen in severity after the first dose of study medication. The grade of an AE was determined according to Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0.
Time frame: Up to 28 days after last dose of study drug (up to 6 years)
Number of Participants With Treatment-Related Adverse Events (AEs) in Non-Randomized Portion
Treatment-related AE was any untoward medical occurrence in a participant with causal relationship to the study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. The grade of an AE was determined according to CTCAE Version 3.0.
Time frame: Up to 28 days after last dose of study drug (up to 6 years)
Number of Participants With Treatment-Emergent Adverse Events (AEs) in Randomized Portion
An AE was an untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes: death, initial or prolonged inpatient hospitalization, life-threatening experience, persistent or significant disability/incapacity, congenital anomaly. Treatment-emergent AEs were those with initial onset or that worsen in severity after the first dose of study medication. The grade of an AE was determined according to CTCAE Version 3.0.
Time frame: Up to 28 days after last dose of study drug (up to 6 years)
Number of Participants With Treatment-Related Adverse Events (AEs) in Randomized Portion
Treatment-related AE was any untoward medical occurrence in a participant with causal relationship to the study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. The grade of an AE was determined according to CTCAE Version 3.0.
Time frame: Up to 28 days after last dose of study drug (up to 6 years)
Total 224 participants were enrolled in the study. Randomized portion enrolled 202 participants in 2 arms (134 in axitinib, 68 in placebo) in 70 centers (13 countries). Non-randomized portion enrolled 22 participants in 2 cohorts (15 in Child-Pugh Class A, 7 in Child-Pugh Class B score 7) according to Child-Pugh score in 13 centers (4 countries).
| Milestone | Child-Pugh Class A | Child-Pugh Class B | Axitinib | Placebo |
|---|---|---|---|---|
| Started | 15 | 7 | 134 | 68 |
| Completed | 0 | 0 | 0 | 0 |
| Not completed | 15 | 7 | 134 | 68 |
| Withdrew: Participant refused further follow-up | 1 | 0 | 11 | 2 |
| Withdrew: Death | 14 | 7 | 112 | 54 |
| Withdrew: Study terminated by sponsor | 0 | 0 | 4 | 11 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 1 |
| Withdrew: Other unspecified | 0 | 0 | 6 | 0 |
OS was defined as the time from the date of randomization to the date of death due to any cause. OS (in months) was calculated as (date of death - first randomization date +1)/30.4. For participants still alive at the time of the analysis, the OS time was censored on the last date they were known to be alive. All participants were followed up for survival at least every 3 months after discontinuing study treatment until at least two years after randomization of the last participant.
| months | Axitinib | Placebo |
|---|---|---|
| Overall Survival (OS) - Stratified Analysis, Randomized Portion | 12.7 (10.2 to 14.9) | 9.7 (5.9 to 11.8) |
PFS was defined as time from randomization to first documented objective tumor progression or to death due to any cause, whichever occurred first. PFS (in months) was calculated as (first event date - first randomization date +1)/30.4. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease \[PD\]), or from adverse event (AE) data (where the outcome was death). As per response evaluation criteria in solid tumors (RECIST) 1.1, progression was defined as greater than or equal to (\>=) 20% increase in sum of longest dimensions of target lesions or appearance of one or more new target lesions and unequivocal progression of existing non-target lesions, or appearance of 1 new non-target lesions. Participants discontinuing study treatment without documented evidence of PD were to be followed up at least every 8 weeks after discontinuing study treatment until disease progression, or initiation of another anticancer treatment.
| months | Axitinib | Placebo |
|---|---|---|
| Progression-Free Survival (PFS) - Stratified Analysis, Randomized Portion | 3.6 (2.3 to 4.6) | 1.9 (1.9 to 3.5) |
ORR was defined as the percentage of participants with confirmed complete response (CR) or confirmed partial response (PR) according to the RECIST 1.1. CR was defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must decrease to normal (short axis \<10 millimetres \[mm\]). PR was defined as a 30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions.
| percentage of participants | Axitinib | Placebo |
|---|---|---|
| Objective Response Rate (ORR) - Percentage of Participants With Objective Response by Stratified Analysis, Randomized Portion | 9.7 (5.3 to 16.0) | 2.9 (0.4 to 10.2) |
TTP was defined as the time from randomization to first documentation of objective tumor progression. If tumor progression data included more than 1 date, the first date was used. TTP (in months) was calculated as (first event date - first randomization date +1)/30.4.
| months | Axitinib | Placebo |
|---|---|---|
| Time to Tumor Progression (TTP) - Stratified Analysis, Randomized Portion | 3.7 (2.8 to 5.6) | 1.9 (1.9 to 3.6) |
DR was defined as the time from the first documentation of objective tumor response (CR or PR) that was subsequently confirmed to the first documentation of PD or to death due to any cause, whichever occurs first. If tumor progression data included more than 1 date, the first date was to be used. DR (in months) was to be calculated as (the end date for DR - first CR or PR that was subsequently confirmed +1)/30.4.
| months | Axitinib | Placebo |
|---|---|---|
| Duration of Response (DR) by Unstratified Analysis, Randomized Portion | 6.4 (3.7 to 9.3) | NA (NA to NA) |
CBR was defined as the percentage of participants with confirmed CR or confirmed PR or a best response of stable disease \>=8 weeks according to RECIST 1.1 criteria, relative to all randomized participants who had baseline measurable disease. Confirmed responses were defined as those that persisted on repeat imaging study \>=4 weeks after the initial documentation of response. Participants who did not have on study radiographic tumor re-evaluation or who died, progressed, or dropped out for any reason prior to reaching a CR, PR, or stable disease were counted as non-responders in the assessment of CBR. A participant who initially met the criteria for a PR and then subsequently became a confirmed CR was to be assigned a best response of CR.
| percentage of participants | Axitinib | Placebo |
|---|---|---|
| Percentage of Participants With Overall Clinical Benefit Response (CBR) - Stratified Analysis, Randomized Portion | 31.3 (23.6 to 39.9) | 11.8 (5.2 to 21.9) |
Axitinib samples were to be collected from all participants on Cycle 1 Day 15 at the following time points: pre-dose, 1, 2, 3, 4, 6 and 8 hours after axitinib dosing.
| nanograms per milliliter (ng/mL) | Child-Pugh Class A | Child-Pugh Class B |
|---|---|---|
| Axitinib Steady-State Pharmacokinetic (PK) Parameter - Maximum Observed Plasma Concentration (Cmax), Non-Randomized Portion | 35.74 (21.84 to 58.50) | 21.16 (11.10 to 40.33) |
Axitinib samples were to be collected from all participants on Cycle 1 Day 15 at the following time points: pre-dose, 1, 2, 3, 4, 6 and 8 hours after axitinib dosing. In the below table, 4 participants in Child-Pugh A and 1 participant in Child-Pugh B were not reported due to nonestimable half-life.
| nanograms*hour per milliliter (ng*hr/mL) | Child-Pugh Class A | Child-Pugh Class B |
|---|---|---|
| Axitinib Steady-State PK Parameter - Area Under the Plasma Concentration Versus Time Curve From 0 to 24 Hour (AUC0-24), Non-Randomized Portion | 310.76 (175.02 to 551.75) | 316.20 (162.96 to 613.55) |
Axitinib samples were to be collected from all participants on Cycle 1 Day 15 at the following time points: pre-dose, 1, 2, 3, 4, 6 and 8 hours after axitinib dosing.
| hours | Child-Pugh Class A | Child-Pugh Class B |
|---|---|---|
| Axitinib Steady-State Pharmacokinetic Parameter - Time to First Occurrence of Cmax (Tmax), Non-Randomized Portion | 2.50 (0.00 to 7.98) | 1.05 (0.00 to 4.00) |
Axitinib samples were to be collected from all participants on Cycle 1 Day 15 at the following time points: pre-dose, 1, 2, 3, 4, 6 and 8 hours after axitinib dosing. In the below table, 4 participants in Child-Pugh A and 1 participant in Child-Pugh B were not reported due to nonestimable half-life.
| liters per hour (L/hr) | Child-Pugh Class A | Child-Pugh Class B |
|---|---|---|
| Axitinib Steady-State Pharmacokinetic Parameter - Apparent Oral Clearance (CL/F), Non-Randomized Portion | 32.18 (18.12 to 57.13) | 12.65 (6.52 to 24.55) |
Axitinib samples were to be collected from all participants on Cycle 1 Day 15 at the following time points: pre-dose, 1, 2, 3, 4, 6 and 8 hours after axitinib dosing. In the below table, 4 participants in Child-Pugh A and 1 participant in Child-Pugh B were not reported due to nonestimable half-life.
| hours | Child-Pugh Class A | Child-Pugh Class B |
|---|---|---|
| Axitinib Steady-State Pharmacokinetic Parameter - Terminal Plasma Elimination Half-Life (t1/2), Non-Randomized Portion | 4.12 ± 3.55 | 4.79 ± 2.42 |
Axitinib samples were to be collected from all participants on Cycle 1 Day 15 at the following time points: pre-dose, 1, 2, 3, 4, 6 and 8 hours after axitinib dosing. The PK parameter, Vz/F has been presented in this outcome measure. In the below table, 4 participants in Child-Pugh A and 1 participant in Child-Pugh B were not reported due to nonestimable half-life.
| liters | Child-Pugh Class A | Child-Pugh Class B |
|---|---|---|
| Axitinib Steady-State Pharmacokinetic Parameter - Apparent Oral Volume of Distribution of the Drug During the Elimination Phase (Vz/F), Non-Randomized Portion | 150.01 ± 3.55 | 81.16 ± 2.42 |
Plasma soluble proteins interleukin-6 (IL-6), E-Selectin, interleukin-8 (IL-8), hepatocyte growth factor (HGF), matrix metalloproteinase-2 (MMP-2), stem cell factor (SCF), angiopoietin-2 (Ang-2), vascular endothelial growth factor-A (VEGF-A), vascular endothelial growth factor-C (VEGF-C), soluble vascular endothelial growth factor receptor 2 (sVEGFR2), soluble vascular endothelial growth factor receptor 3 (sVEGFR3), stromal cell-derived factor-1 (SDF1), neutrophil gelatinase-associated lipocalin (NGAL), migration inhibitory factor (MIF), c-MET, regulated upon activation normal T cell expressed and presumably secreted (RANTES), and monocyte chemotactic protein-3 (MCP-3) were only measured in randomized participants.
| picograms per milliliter (pg/mL) | Axitinib | Placebo |
|---|---|---|
| IL-6 | 50.67 ± 102.86 | 50.72 ± 106.74 |
| E-Selectin | 52313.94 ± 32603.18 | 55430.76 ± 26723.43 |
| IL-8 | 33.35 ± 47.72 | 27.23 ± 44.46 |
| HGF | 478.84 ± 712.43 | 406.06 ± 376.04 |
| MMP-2 | 355715.66 ± 137663.04 | 350979.72 ± 146323.29 |
| SCF | 1352.75 ± 1534.41 | 1439.71 ± 2260.89 |
| Ang-2 | 662.40 ± 623.87 | 577.82 ± 354.42 |
| VEGF-A | 102.56 ± 128.09 | 173.59 ± 472.19 |
| VEGF-C | NA ± NA | NA ± NA |
| sVEGFR2 | 17675.76 ± 7218.95 | 18273.65 ± 6836.16 |
| sVEGFR3 | 287429.28 ± 117583.24 | 290338.69 ± 97830.36 |
| SDF1 | 1190.08 ± 823.03 | 1150.10 ± 681.04 |
| NGAL | 134861.80 ± 152492.96 | 141383.00 ± 121747.35 |
| MIF | 33057.15 ± 28256.00 | 32302.99 ± 21485.01 |
| c-MET ELISA | 1664.96 ± 834.36 | 1641.08 ± 704.38 |
| RANTES | 26412.12 ± 38682.81 | 26917.76 ± 27094.12 |
| MCP-3 | NA ± NA | NA ± NA |
A 5 millilitres (mL) whole blood sample was collected from all randomized participants to evaluate the miRNA transcripts.
| percentage of participants | Axitinib | Placebo |
|---|---|---|
| hsa-let-7a-5p | 100.0 | 100.0 |
| hsa-let-7b-5p | 100.0 | 100.0 |
| hsa-let-7c | 100.0 | 100.0 |
| hsa-let-7d-5p | 100.0 | 100.0 |
| hsa-let-7f-5p | 100.0 | 100.0 |
| hsa-let-7g-5p | 100.0 | 100.0 |
| hsa-let-7i-5p | 100.0 | 100.0 |
| hsa-miR-103a-3p | 100.0 | 100.0 |
| hsa-miR-106b-5p | 100.0 | 100.0 |
| hsa-miR-107 | 100.0 | 100.0 |
| hsa-miR-1202 | 100.0 | 100.0 |
| hsa-miR-1207-5p | 100.0 | 100.0 |
| hsa-miR-1225-5p | 100.0 | 100.0 |
| hsa-miR-1234-5p | 100.0 | 100.0 |
| hsa-miR-1246 | 100.0 | 100.0 |
| hsa-miR-125b-5p | 100.0 | 100.0 |
| hsa-miR-126-3p | 100.0 | 100.0 |
| hsa-miR-1260a | 100.0 | 100.0 |
| hsa-miR-1260b | 100.0 | 100.0 |
| hsa-miR-1268a | 100.0 | 100.0 |
| hsa-miR-1273g-3p | 100.0 | 100.0 |
| hsa-miR-1275 | 100.0 | 100.0 |
| hsa-miR-128 | 100.0 | 100.0 |
| hsa-miR-130a-3p | 100.0 | 100.0 |
| hsa-miR-130b-3p | 100.0 | 100.0 |
| hsa-miR-140-3p | 100.0 | 100.0 |
| hsa-miR-142-3p | 100.0 | 100.0 |
| hsa-miR-145-5p | 100.0 | 100.0 |
| hsa-miR-148a-3p | 100.0 | 100.0 |
| hsa-miR-148b-3p | 100.0 | 100.0 |
| hsa-miR-150-5p | 100.0 | 100.0 |
| hsa-miR-151a-3p | 100.0 | 100.0 |
| hsa-miR-151a-5p | 100.0 | 100.0 |
| hsa-miR-151b | 100.0 | 100.0 |
| hsa-miR-1587 | 100.0 | 100.0 |
| hsa-miR-15a-5p | 100.0 | 100.0 |
| hsa-miR-15b-5p | 100.0 | 100.0 |
| hsa-miR-16-5p | 100.0 | 100.0 |
| hsa-miR-17-5p | 100.0 | 100.0 |
| hsa-miR-181a-5p | 100.0 | 100.0 |
| hsa-miR-182-5p | 100.0 | 100.0 |
| hsa-miR-183-5p | 100.0 | 100.0 |
| hsa-miR-185-5p | 100.0 | 100.0 |
| hsa-miR-186-5p | 100.0 | 100.0 |
| hsa-miR-191-5p | 100.0 | 100.0 |
| hsa-miR-1914-3p | 100.0 | 100.0 |
| hsa-miR-1915-3p | 100.0 | 100.0 |
| hsa-miR-192-5p | 100.0 | 100.0 |
| hsa-miR-194-5p | 100.0 | 100.0 |
| hsa-miR-197-3p | 100.0 | 100.0 |
| hsa-miR-197-5p | 100.0 | 100.0 |
| hsa-miR-19a-3p | 100.0 | 100.0 |
| hsa-miR-19b-3p | 100.0 | 100.0 |
| hsa-miR-20a-5p | 100.0 | 100.0 |
| hsa-miR-20b-5p | 100.0 | 100.0 |
| hsa-miR-21-5p | 100.0 | 100.0 |
| hsa-miR-210 | 100.0 | 100.0 |
| hsa-miR-215 | 100.0 | 100.0 |
| hsa-miR-22-3p | 100.0 | 100.0 |
| hsa-miR-222-3p | 100.0 | 100.0 |
| hsa-miR-223-3p | 100.0 | 100.0 |
| hsa-miR-23a-3p | 100.0 | 100.0 |
| hsa-miR-23b-3p | 100.0 | 100.0 |
| hsa-miR-24-3p | 100.0 | 100.0 |
| hsa-miR-25-3p | 100.0 | 100.0 |
| hsa-miR-26a-5p | 100.0 | 100.0 |
| hsa-miR-26b-5p | 100.0 | 100.0 |
| hsa-miR-2861 | 100.0 | 100.0 |
| hsa-miR-29a-3p | 100.0 | 100.0 |
| hsa-miR-29b-3p | 100.0 | 100.0 |
| hsa-miR-29c-3p | 100.0 | 100.0 |
| hsa-miR-29c-5p | 100.0 | 100.0 |
| hsa-miR-30b-5p | 100.0 | 100.0 |
| hsa-miR-30c-5p | 100.0 | 100.0 |
| hsa-miR-30d-5p | 100.0 | 100.0 |
| hsa-miR-30e-5p | 100.0 | 100.0 |
| hsa-miR-3135b | 100.0 | 100.0 |
| hsa-miR-3162-5p | 100.0 | 100.0 |
| hsa-miR-3180-3p | 100.0 | 100.0 |
| hsa-miR-3195 | 100.0 | 100.0 |
| hsa-miR-320a | 100.0 | 100.0 |
| hsa-miR-320b | 100.0 | 100.0 |
| hsa-miR-320c | 100.0 | 100.0 |
| hsa-miR-320d | 100.0 | 100.0 |
| hsa-miR-320e | 100.0 | 100.0 |
| hsa-miR-324-3p | 100.0 | 100.0 |
| hsa-miR-324-5p | 100.0 | 100.0 |
| hsa-miR-331-3p | 100.0 | 100.0 |
| hsa-miR-339-5p | 100.0 | 100.0 |
| hsa-miR-342-3p | 100.0 | 100.0 |
| hsa-miR-361-3p | 100.0 | 100.0 |
| hsa-miR-361-5p | 100.0 | 100.0 |
| hsa-miR-362-5p | 100.0 | 100.0 |
| hsa-miR-363-3p | 100.0 | 100.0 |
| hsa-miR-3651 | 100.0 | 100.0 |
| hsa-miR-3656 | 100.0 | 100.0 |
| hsa-miR-365a-3p | 100.0 | 100.0 |
| hsa-miR-3665 | 100.0 | 100.0 |
| hsa-miR-3676-5p | 100.0 | 100.0 |
| hsa-miR-374b-5p | 100.0 | 100.0 |
| hsa-miR-378a-3p | 100.0 | 100.0 |
| hsa-miR-378i | 100.0 | 100.0 |
| hsa-miR-3940-5p | 100.0 | 100.0 |
| hsa-miR-3960 | 100.0 | 100.0 |
| hsa-miR-423-3p | 100.0 | 100.0 |
| hsa-miR-425-5p | 100.0 | 100.0 |
| hsa-miR-4281 | 100.0 | 100.0 |
| hsa-miR-4284 | 100.0 | 100.0 |
| hsa-miR-4286 | 100.0 | 100.0 |
| hsa-miR-4299 | 100.0 | 100.0 |
| hsa-miR-4306 | 100.0 | 100.0 |
| hsa-miR-4318 | 100.0 | 100.0 |
| hsa-miR-4323 | 100.0 | 100.0 |
| hsa-miR-4428 | 100.0 | 100.0 |
| hsa-miR-4442 | 100.0 | 100.0 |
| hsa-miR-4443 | 100.0 | 100.0 |
| hsa-miR-4454 | 100.0 | 100.0 |
| hsa-miR-4459 | 100.0 | 100.0 |
| hsa-miR-4466 | 100.0 | 100.0 |
| hsa-miR-4497 | 100.0 | 100.0 |
| hsa-miR-4505 | 100.0 | 100.0 |
| hsa-miR-4507 | 100.0 | 100.0 |
| hsa-miR-4516 | 100.0 | 100.0 |
| hsa-miR-451a | 100.0 | 100.0 |
| hsa-miR-4530 | 100.0 | 100.0 |
| hsa-miR-4687-3p | 100.0 | 100.0 |
| hsa-miR-4713-3p | 100.0 | 100.0 |
| hsa-miR-4721 | 100.0 | 100.0 |
| hsa-miR-4728-5p | 100.0 | 100.0 |
| hsa-miR-4732-3p | 100.0 | 100.0 |
| hsa-miR-4739 | 100.0 | 100.0 |
| hsa-miR-4763-3p | 100.0 | 100.0 |
| hsa-miR-4787-5p | 100.0 | 100.0 |
| hsa-miR-4788 | 100.0 | 100.0 |
| hsa-miR-484 | 100.0 | 100.0 |
| hsa-miR-486-5p | 100.0 | 100.0 |
| hsa-miR-494 | 100.0 | 100.0 |
| hsa-miR-5001-5p | 100.0 | 100.0 |
| hsa-miR-500a-3p | 100.0 | 100.0 |
| hsa-miR-500a-5p | 100.0 | 100.0 |
| hsa-miR-501-3p | 100.0 | 100.0 |
| hsa-miR-501-5p | 100.0 | 100.0 |
| hsa-miR-502-3p | 100.0 | 100.0 |
| hsa-miR-505-5p | 100.0 | 100.0 |
| hsa-miR-5100 | 100.0 | 100.0 |
| hsa-miR-532-3p | 100.0 | 100.0 |
| hsa-miR-532-5p | 100.0 | 100.0 |
| hsa-miR-550a-3-5p | 100.0 | 100.0 |
| hsa-miR-550a-3p | 100.0 | 100.0 |
| hsa-miR-5739 | 100.0 | 100.0 |
| hsa-miR-574-3p | 100.0 | 100.0 |
| hsa-miR-574-5p | 100.0 | 100.0 |
| hsa-miR-5787 | 100.0 | 100.0 |
| hsa-miR-584-5p | 100.0 | 100.0 |
| hsa-miR-6085 | 100.0 | 100.0 |
| hsa-miR-6087 | 100.0 | 100.0 |
| hsa-miR-6088 | 100.0 | 100.0 |
| hsa-miR-6089 | 100.0 | 100.0 |
| hsa-miR-6090 | 100.0 | 100.0 |
| hsa-miR-6125 | 100.0 | 100.0 |
| hsa-miR-6127 | 100.0 | 100.0 |
| hsa-miR-625-5p | 100.0 | 100.0 |
| hsa-miR-638 | 100.0 | 100.0 |
| hsa-miR-642a-3p | 100.0 | 100.0 |
| hsa-miR-642b-3p | 100.0 | 100.0 |
| hsa-miR-652-3p | 100.0 | 100.0 |
| hsa-miR-660-5p | 100.0 | 100.0 |
| hsa-miR-664a-3p | 100.0 | 100.0 |
| hsa-miR-664b-3p | 100.0 | 100.0 |
| hsa-miR-6717-5p | 100.0 | 100.0 |
| hsa-miR-6724-5p | 100.0 | 100.0 |
| hsa-miR-7-5p | 100.0 | 100.0 |
| hsa-miR-762 | 100.0 | 100.0 |
| hsa-miR-766-3p | 100.0 | 100.0 |
| hsa-miR-92a-3p | 100.0 | 100.0 |
| hsa-miR-93-3p | 100.0 | 100.0 |
| hsa-miR-93-5p | 100.0 | 100.0 |
| hsa-miR-937-5p | 100.0 | 100.0 |
| hsa-miR-940 | 100.0 | 100.0 |
| hsa-miR-1228-3p | 99.1 | 100.0 |
| hsa-miR-1268b | 99.1 | 100.0 |
| hsa-miR-142-5p | 100.0 | 98.3 |
| hsa-miR-27a-3p | 99.1 | 100.0 |
| hsa-miR-296-5p | 99.1 | 100.0 |
| hsa-miR-3196 | 99.1 | 100.0 |
| hsa-miR-3198 | 99.1 | 100.0 |
| hsa-miR-342-5p | 100.0 | 98.3 |
| hsa-miR-3653 | 100.0 | 98.3 |
| hsa-miR-4465 | 99.1 | 100.0 |
| hsa-miR-4515 | 99.1 | 100.0 |
| hsa-miR-4653-3p | 99.1 | 100.0 |
| hsa-miR-4665-3p | 99.1 | 100.0 |
| hsa-miR-4746-3p | 99.1 | 100.0 |
| hsa-miR-505-3p | 100.0 | 98.3 |
| hsa-miR-6073 | 99.1 | 100.0 |
| hsa-miR-6126 | 99.1 | 100.0 |
| hsa-miR-6132 | 99.1 | 100.0 |
| hsa-miR-6165 | 99.1 | 100.0 |
| hsa-miR-744-5p | 100.0 | 98.3 |
| hsa-miR-874 | 99.1 | 100.0 |
| hsa-miR-942 | 100.0 | 98.3 |
| hsa-miR-96-5p | 99.1 | 100.0 |
| hsa-miR-1238-3p | 98.2 | 100.0 |
| hsa-miR-1285-3p | 99.1 | 98.3 |
| hsa-miR-1305 | 98.2 | 100.0 |
| hsa-miR-146a-5p | 98.2 | 100.0 |
| hsa-miR-15b-3p | 99.1 | 98.3 |
| hsa-miR-17-3p | 98.2 | 100.0 |
| hsa-miR-195-5p | 99.1 | 98.3 |
| hsa-miR-199a-5p | 99.1 | 98.3 |
| hsa-miR-28-5p | 99.1 | 98.3 |
| hsa-miR-30a-5p | 99.1 | 98.3 |
| hsa-miR-340-3p | 99.1 | 98.3 |
| hsa-miR-3679-5p | 99.1 | 98.3 |
| hsa-miR-374a-5p | 99.1 | 98.3 |
| hsa-miR-378a-5p | 99.1 | 98.3 |
| hsa-miR-4433-5p | 98.2 | 100.0 |
| hsa-miR-454-3p | 99.1 | 98.3 |
| hsa-miR-4685-5p | 99.1 | 98.3 |
| hsa-miR-575 | 98.2 | 100.0 |
| hsa-miR-6068 | 98.2 | 100.0 |
| hsa-miR-6124 | 98.2 | 100.0 |
| hsa-miR-6131 | 98.2 | 100.0 |
| hsa-miR-939-5p | 98.2 | 100.0 |
| hsa-miR-1234-3p | 99.1 | 96.6 |
| hsa-miR-1249 | 98.2 | 98.3 |
| hsa-miR-132-3p | 99.1 | 96.6 |
| hsa-miR-30e-3p | 98.2 | 98.3 |
| hsa-miR-326 | 99.1 | 96.6 |
| hsa-miR-374c-5p | 98.2 | 98.3 |
| hsa-miR-4270 | 97.3 | 100.0 |
| hsa-miR-4672 | 97.3 | 100.0 |
| hsa-miR-4741 | 98.2 | 98.3 |
| hsa-miR-6515-3p | 97.3 | 100.0 |
| hsa-miR-371b-5p | 97.3 | 98.3 |
| hsa-miR-4485 | 96.4 | 100.0 |
| hsa-miR-4513 | 98.2 | 96.6 |
| hsa-miR-454-5p | 98.2 | 96.6 |
| hsa-miR-4716-3p | 96.4 | 100.0 |
| hsa-miR-5006-5p | 97.3 | 98.3 |
| hsa-miR-6069 | 98.2 | 96.6 |
| hsa-miR-101-3p | 97.3 | 96.6 |
| hsa-miR-155-5p | 97.3 | 96.6 |
| hsa-miR-16-2-3p | 98.2 | 94.9 |
| hsa-miR-27b-3p | 98.2 | 94.9 |
| hsa-miR-328 | 98.2 | 94.9 |
| hsa-miR-4486 | 96.4 | 98.3 |
| hsa-miR-513a-5p | 96.4 | 98.3 |
| hsa-miR-92b-3p | 98.2 | 94.9 |
| hsa-miR-98-5p | 98.2 | 94.9 |
| hsa-miR-18b-5p | 96.4 | 96.6 |
| hsa-miR-191-3p | 97.3 | 94.9 |
| hsa-miR-3200-5p | 97.3 | 94.9 |
| hsa-miR-4313 | 97.3 | 94.9 |
| hsa-miR-4532 | 96.4 | 96.6 |
| hsa-miR-4787-3p | 97.3 | 94.9 |
| hsa-miR-513b | 95.5 | 98.3 |
| hsa-miR-550a-5p | 97.3 | 94.9 |
| hsa-miR-5581-5p | 94.6 | 100.0 |
| hsa-miR-629-3p | 97.3 | 94.9 |
| hsa-miR-629-5p | 94.6 | 100.0 |
| hsa-miR-7-1-3p | 98.2 | 93.2 |
| hsa-miR-125a-3p | 94.6 | 98.3 |
| hsa-miR-1281 | 97.3 | 93.2 |
| hsa-miR-140-5p | 95.5 | 96.6 |
| hsa-miR-144-5p | 96.4 | 94.9 |
| hsa-let-7b-3p | 96.4 | 93.2 |
| hsa-let-7f-1-3p | 95.5 | 94.9 |
| hsa-miR-125a-5p | 96.4 | 93.2 |
| hsa-miR-183-3p | 96.4 | 93.2 |
| hsa-miR-3162-3p | 97.3 | 91.5 |
| hsa-miR-33b-3p | 97.3 | 91.5 |
| hsa-miR-4669 | 94.6 | 96.6 |
| hsa-miR-502-5p | 96.4 | 93.2 |
| hsa-miR-1304-3p | 97.3 | 89.8 |
| hsa-miR-1306-5p | 95.5 | 93.2 |
| hsa-miR-221-3p | 93.7 | 96.6 |
| hsa-miR-4649-3p | 96.4 | 91.5 |
| hsa-miR-4690-5p | 94.6 | 94.9 |
| hsa-miR-627 | 95.5 | 93.2 |
| hsa-miR-99a-5p | 96.4 | 91.5 |
| hsa-miR-18a-5p | 94.6 | 93.2 |
| hsa-miR-211-3p | 94.6 | 93.2 |
| hsa-miR-4430 | 95.5 | 91.5 |
| hsa-miR-6508-5p | 95.5 | 91.5 |
| hsa-miR-933 | 95.5 | 91.5 |
| hsa-miR-339-3p | 94.6 | 91.5 |
| hsa-miR-624-5p | 95.5 | 89.8 |
| hsa-miR-425-3p | 95.5 | 88.1 |
| hsa-miR-5194 | 91.9 | 93.2 |
| hsa-miR-6511b-3p | 92.8 | 91.5 |
| hsa-let-7d-3p | 92.8 | 89.8 |
| hsa-miR-129-2-3p | 92.8 | 89.8 |
| hsa-miR-1825 | 92.8 | 89.8 |
| hsa-miR-362-3p | 93.7 | 88.1 |
| hsa-miR-665 | 91.0 | 93.2 |
| hsa-miR-149-5p | 92.8 | 88.1 |
| hsa-miR-3620-5p | 91.0 | 91.5 |
| hsa-miR-4478 | 90.1 | 91.5 |
| hsa-miR-4484 | 92.8 | 86.4 |
| hsa-miR-4656 | 90.1 | 91.5 |
| hsa-miR-602 | 91.9 | 88.1 |
| hsa-miR-1233-1-5p | 89.2 | 91.5 |
| hsa-miR-3125 | 89.2 | 91.5 |
| hsa-miR-4725-5p | 91.0 | 88.1 |
| hsa-miR-4732-5p | 91.0 | 88.1 |
| hsa-miR-146b-5p | 92.8 | 83.1 |
| hsa-miR-4659a-3p | 91.0 | 86.4 |
| hsa-miR-6510-5p | 88.3 | 91.5 |
| hsa-miR-1225-3p | 91.0 | 84.7 |
| hsa-miR-1539 | 90.1 | 86.4 |
| hsa-miR-188-5p | 88.3 | 89.8 |
| hsa-miR-4758-3p | 91.0 | 84.7 |
| hsa-miR-550b-2-5p | 91.9 | 83.1 |
| hsa-miR-144-3p | 89.2 | 86.4 |
| hsa-miR-4310 | 89.2 | 84.7 |
| hsa-miR-4749-3p | 89.2 | 84.7 |
| hsa-miR-1229-5p | 87.4 | 86.4 |
| hsa-miR-1288 | 86.5 | 88.1 |
| hsa-miR-3156-5p | 84.7 | 91.5 |
| hsa-miR-2116-3p | 89.2 | 81.4 |
| hsa-miR-4664-3p | 87.4 | 84.7 |
| hsa-miR-23c | 87.4 | 83.1 |
| hsa-miR-3652 | 85.6 | 86.4 |
| hsa-miR-424-5p | 88.3 | 81.4 |
| hsa-miR-4745-5p | 85.6 | 86.4 |
| hsa-miR-1973 | 83.8 | 88.1 |
| hsa-miR-4291 | 84.7 | 86.4 |
| hsa-miR-3200-3p | 86.5 | 81.4 |
| hsa-miR-4436b-5p | 84.7 | 84.7 |
| hsa-miR-6512-5p | 82.9 | 88.1 |
| hsa-miR-3613-3p | 86.5 | 78.0 |
| hsa-miR-4793-5p | 81.1 | 88.1 |
| hsa-miR-628-3p | 83.8 | 83.1 |
| hsa-miR-1181 | 82.9 | 83.1 |
| hsa-miR-3646 | 82.0 | 84.7 |
| hsa-miR-4317 | 82.9 | 83.1 |
| hsa-miR-5684 | 83.8 | 81.4 |
| hsa-miR-1227-5p | 81.1 | 84.7 |
| hsa-miR-3180-5p | 84.7 | 78.0 |
| hsa-miR-4665-5p | 82.9 | 81.4 |
| hsa-miR-129-1-3p | 82.0 | 81.4 |
| hsa-miR-4652-3p | 82.9 | 79.7 |
| hsa-miR-500b | 82.0 | 79.7 |
| hsa-miR-181b-5p | 83.8 | 74.6 |
| hsa-miR-3676-3p | 82.9 | 76.3 |
| hsa-miR-671-5p | 77.5 | 86.4 |
| hsa-miR-1185-1-3p | 78.4 | 83.1 |
| hsa-miR-378d | 78.4 | 83.1 |
| hsa-miR-1271-5p | 81.1 | 76.3 |
| hsa-miR-4433-3p | 78.4 | 81.4 |
| hsa-miR-564 | 81.1 | 76.3 |
| hsa-miR-6723-5p | 81.1 | 76.3 |
| hsa-miR-100-5p | 82.9 | 71.2 |
| hsa-miR-135a-3p | 77.5 | 81.4 |
| hsa-miR-181a-2-3p | 80.2 | 76.3 |
| hsa-miR-4666b | 78.4 | 79.7 |
| hsa-miR-98-3p | 79.3 | 76.3 |
| hsa-miR-3940-3p | 77.5 | 74.6 |
| hsa-miR-513c-5p | 74.8 | 79.7 |
| hsa-miR-634 | 79.3 | 71.2 |
| hsa-miR-4769-3p | 77.5 | 72.9 |
| hsa-miR-6507-3p | 76.6 | 72.9 |
| hsa-miR-3907 | 72.1 | 79.7 |
| hsa-miR-4634 | 73.0 | 78.0 |
| hsa-miR-563 | 73.9 | 74.6 |
| hsa-miR-892b | 73.9 | 74.6 |
| hsa-miR-103a-2-5p | 74.8 | 71.2 |
| hsa-miR-2392 | 73.9 | 72.9 |
| hsa-miR-3127-5p | 72.1 | 76.3 |
| hsa-miR-338-5p | 73.0 | 74.6 |
| hsa-miR-3614-5p | 73.9 | 72.9 |
| hsa-miR-4499 | 70.3 | 79.7 |
| hsa-miR-3667-5p | 74.8 | 69.5 |
| hsa-miR-1290 | 68.5 | 78.0 |
| hsa-miR-130b-5p | 75.7 | 62.7 |
| hsa-miR-4449 | 73.0 | 67.8 |
| hsa-miR-4695-5p | 70.3 | 67.8 |
| hsa-miR-4271 | 67.6 | 71.2 |
| hsa-miR-4651 | 69.4 | 67.8 |
| hsa-miR-340-5p | 63.1 | 74.6 |
| hsa-miR-133b | 67.6 | 61.0 |
| hsa-miR-199b-5p | 70.3 | 55.9 |
| hsa-miR-200c-3p | 67.6 | 61.0 |
| hsa-miR-4257 | 63.1 | 69.5 |
| hsa-miR-150-3p | 62.2 | 69.5 |
| hsa-miR-30c-1-3p | 68.5 | 57.6 |
| hsa-miR-139-3p | 64.9 | 62.7 |
| hsa-miR-625-3p | 62.2 | 67.8 |
| hsa-miR-106b-3p | 67.6 | 54.2 |
| hsa-miR-409-3p | 63.1 | 62.7 |
| hsa-miR-1237-3p | 63.1 | 61.0 |
| hsa-miR-5571-5p | 66.7 | 54.2 |
| hsa-miR-652-5p | 63.1 | 61.0 |
| hsa-miR-196b-5p | 61.3 | 62.7 |
| hsa-miR-22-5p | 64.9 | 55.9 |
| hsa-miR-338-3p | 64.0 | 55.9 |
| hsa-miR-26b-3p | 62.2 | 55.9 |
| hsa-miR-4261 | 55.9 | 67.8 |
| hsa-miR-345-5p | 60.4 | 57.6 |
| hsa-miR-10a-5p | 58.6 | 59.3 |
| hsa-miR-3176 | 56.8 | 62.7 |
| hsa-miR-1224-5p | 56.8 | 61.0 |
| hsa-miR-4462 | 55.9 | 62.7 |
| hsa-miR-4728-3p | 58.6 | 57.6 |
| hsa-miR-193a-5p | 59.5 | 54.2 |
| hsa-miR-664b-5p | 55.9 | 61.0 |
| hsa-miR-3141 | 53.2 | 64.4 |
| hsa-miR-6075 | 55.9 | 59.3 |
| hsa-miR-6086 | 55.0 | 61.0 |
| hsa-miR-99b-5p | 55.9 | 59.3 |
| hsa-miR-1307-3p | 58.6 | 52.5 |
| hsa-miR-148b-5p | 56.8 | 55.9 |
| hsa-miR-15a-3p | 59.5 | 50.8 |
| hsa-miR-6513-3p | 61.3 | 47.5 |
| hsa-miR-590-5p | 54.1 | 57.6 |
| hsa-miR-199a-3p | 52.3 | 59.3 |
| hsa-miR-301a-3p | 55.0 | 52.5 |
| hsa-miR-4698 | 51.4 | 59.3 |
| hsa-miR-491-5p | 56.8 | 49.2 |
| hsa-miR-4701-5p | 53.2 | 54.2 |
| hsa-miR-572 | 53.2 | 54.2 |
| hsa-let-7e-5p | 52.3 | 54.2 |
| hsa-miR-134 | 52.3 | 54.2 |
| hsa-miR-335-5p | 51.4 | 54.2 |
| hsa-miR-4646-3p | 54.1 | 49.2 |
| hsa-miR-4463 | 51.4 | 52.5 |
| hsa-miR-5690 | 56.8 | 39.0 |
| hsa-miR-1972 | 46.8 | 50.8 |
| hsa-miR-769-5p | 48.6 | 47.5 |
| hsa-miR-126-5p | 43.2 | 55.9 |
| hsa-miR-192-3p | 52.3 | 39.0 |
| hsa-miR-4800-5p | 42.3 | 52.5 |
| hsa-miR-212-3p | 42.3 | 50.8 |
| hsa-miR-5010-3p | 43.2 | 49.2 |
| hsa-miR-641 | 48.6 | 39.0 |
| hsa-miR-3648 | 40.5 | 50.8 |
| hsa-miR-548ai | 45.9 | 40.7 |
| hsa-miR-3663-3p | 42.3 | 44.1 |
| hsa-miR-4298 | 38.7 | 49.2 |
| hsa-miR-4707-3p | 41.4 | 44.1 |
| hsa-miR-1273e | 38.7 | 47.5 |
| hsa-miR-487b | 36.9 | 49.2 |
| hsa-miR-1227-3p | 40.5 | 40.7 |
| hsa-miR-18a-3p | 43.2 | 35.6 |
| hsa-miR-769-3p | 40.5 | 39.0 |
| hsa-miR-598 | 39.6 | 39.0 |
| hsa-miR-1273f | 38.7 | 37.3 |
| hsa-miR-663a | 38.7 | 37.3 |
| hsa-miR-2110 | 36.9 | 39.0 |
| hsa-miR-371a-5p | 34.2 | 42.4 |
| hsa-miR-483-3p | 36.0 | 39.0 |
| hsa-miR-5195-3p | 37.8 | 35.6 |
| hsa-miR-654-3p | 35.1 | 35.6 |
| hsa-miR-877-3p | 34.2 | 37.3 |
| hsa-miR-3190-5p | 34.2 | 35.6 |
| hsa-miR-4697-5p | 34.2 | 35.6 |
| hsa-miR-617 | 36.0 | 32.2 |
| hsa-miR-4324 | 35.1 | 30.5 |
| hsa-miR-4534 | 31.5 | 35.6 |
| hsa-miR-4633-5p | 28.8 | 39.0 |
| hsa-miR-4538 | 27.9 | 39.0 |
| hsa-miR-664a-5p | 29.7 | 35.6 |
| hsa-miR-4312 | 26.1 | 37.3 |
| hsa-miR-6076 | 25.2 | 35.6 |
| hsa-miR-5585-3p | 28.8 | 27.1 |
| hsa-miR-125b-1-3p | 25.2 | 32.2 |
| hsa-miR-4632-5p | 27.0 | 28.8 |
| hsa-miR-139-5p | 27.9 | 25.4 |
| hsa-miR-4767 | 33.3 | 15.3 |
| hsa-miR-34a-5p | 27.9 | 22.0 |
| hsa-miR-4455 | 25.2 | 27.1 |
| hsa-miR-330-3p | 28.8 | 18.6 |
| hsa-miR-1180 | 25.2 | 23.7 |
| hsa-miR-193b-3p | 28.8 | 16.9 |
| hsa-miR-4784 | 20.7 | 30.5 |
| hsa-miR-4667-5p | 23.4 | 23.7 |
| hsa-miR-660-3p | 23.4 | 23.7 |
| hsa-miR-4731-3p | 22.5 | 23.7 |
| hsa-miR-503-5p | 24.3 | 20.3 |
| hsa-miR-378g | 18.0 | 27.1 |
| hsa-miR-4481 | 19.8 | 23.7 |
| hsa-miR-138-2-3p | 18.9 | 23.7 |
| hsa-miR-1469 | 20.7 | 20.3 |
| hsa-miR-4327 | 21.6 | 18.6 |
| hsa-miR-1236-5p | 17.1 | 23.7 |
| hsa-miR-152 | 18.0 | 22.0 |
| hsa-miR-21-3p | 18.9 | 20.3 |
| hsa-miR-4697-3p | 16.2 | 25.4 |
| hsa-miR-548aa | 17.1 | 23.7 |
| hsa-miR-636 | 19.8 | 18.6 |
| hsa-miR-767-3p | 18.0 | 22.0 |
| hsa-miR-4689 | 23.4 | 8.5 |
| hsa-miR-3679-3p | 19.8 | 13.6 |
| hsa-miR-4326 | 15.3 | 22.0 |
| hsa-miR-2276 | 17.1 | 16.9 |
| hsa-miR-3137 | 17.1 | 16.9 |
| hsa-miR-4734 | 16.2 | 18.6 |
| hsa-miR-181c-5p | 18.0 | 13.6 |
| hsa-miR-921 | 17.1 | 15.3 |
| hsa-miR-3688-3p | 15.3 | 16.9 |
| hsa-miR-4274 | 15.3 | 16.9 |
| hsa-miR-4758-5p | 16.2 | 13.6 |
| hsa-miR-5010-5p | 15.3 | 15.3 |
| hsa-miR-4488 | 13.5 | 16.9 |
| hsa-miR-483-5p | 14.4 | 15.3 |
| hsa-miR-542-5p | 15.3 | 13.6 |
| hsa-miR-623 | 11.7 | 20.3 |
| hsa-miR-650 | 9.9 | 23.7 |
| hsa-miR-3188 | 11.7 | 18.6 |
| hsa-miR-378b | 10.8 | 20.3 |
| hsa-miR-576-5p | 12.6 | 16.9 |
| hsa-miR-20a-3p | 15.3 | 10.2 |
| hsa-miR-4487 | 15.3 | 10.2 |
| hsa-miR-1976 | 12.6 | 13.6 |
| hsa-miR-3605-3p | 12.6 | 13.6 |
| hsa-miR-4647 | 9.9 | 18.6 |
| hsa-miR-4700-3p | 11.7 | 15.3 |
| hsa-miR-6503-3p | 12.6 | 13.6 |
| hsa-miR-3615 | 10.8 | 13.6 |
| hsa-miR-424-3p | 10.8 | 13.6 |
| hsa-miR-4636 | 11.7 | 11.9 |
| hsa-miR-4646-5p | 9.0 | 16.9 |
| hsa-miR-3610 | 12.6 | 8.5 |
| hsa-miR-557 | 9.9 | 13.6 |
| hsa-miR-718 | 14.4 | 5.1 |
| hsa-miR-193b-5p | 9.0 | 13.6 |
| hsa-miR-3692-5p | 12.6 | 6.8 |
| hsa-miR-509-3-5p | 11.7 | 8.5 |
| hsa-miR-1470 | 10.8 | 8.5 |
| hsa-miR-28-3p | 8.1 | 13.6 |
| hsa-miR-378f | 10.8 | 8.5 |
| hsa-miR-4252 | 6.3 | 16.9 |
| hsa-miR-4417 | 11.7 | 6.8 |
| hsa-miR-4498 | 10.8 | 8.5 |
| hsa-miR-491-3p | 8.1 | 13.6 |
| hsa-miR-495-3p | 7.2 | 15.3 |
| hsa-miR-5096 | 12.6 | 5.1 |
| hsa-miR-1229-3p | 6.3 | 15.3 |
| hsa-miR-299-5p | 6.3 | 15.3 |
| hsa-miR-3138 | 6.3 | 15.3 |
| hsa-miR-335-3p | 8.1 | 11.9 |
| hsa-miR-3682-3p | 8.1 | 11.9 |
| hsa-miR-485-3p | 8.1 | 11.9 |
| hsa-miR-630 | 7.2 | 13.6 |
| hsa-miR-936 | 9.0 | 10.2 |
| hsa-miR-101-5p | 10.8 | 5.1 |
| hsa-miR-122-5p | 9.9 | 6.8 |
| hsa-miR-4446-3p | 5.4 | 15.3 |
| hsa-miR-4518 | 8.1 | 10.2 |
| hsa-miR-4640-3p | 6.3 | 13.6 |
| hsa-miR-5189 | 8.1 | 10.2 |
| hsa-miR-6129 | 8.1 | 10.2 |
| hsa-miR-1471 | 8.1 | 8.5 |
| hsa-miR-29b-2-5p | 8.1 | 8.5 |
| hsa-miR-5003-5p | 5.4 | 13.6 |
| hsa-miR-1273c | 6.3 | 10.2 |
| hsa-miR-190a | 9.0 | 5.1 |
| hsa-miR-3675-3p | 8.1 | 6.8 |
| hsa-miR-6511b-5p | 5.4 | 11.9 |
| hsa-miR-1291 | 4.5 | 11.9 |
| hsa-miR-3934-5p | 4.5 | 11.9 |
| hsa-miR-4737 | 7.2 | 6.8 |
| hsa-miR-486-3p | 6.3 | 8.5 |
| hsa-miR-5580-3p | 2.7 | 15.3 |
| hsa-miR-671-3p | 7.2 | 6.8 |
| hsa-miR-154-5p | 6.3 | 6.8 |
| hsa-miR-3158-5p | 7.2 | 5.1 |
| hsa-miR-337-3p | 3.6 | 11.9 |
| hsa-miR-363-5p | 4.5 | 10.2 |
| hsa-miR-376a-3p | 3.6 | 11.9 |
| hsa-miR-5190 | 3.6 | 11.9 |
| hsa-miR-5701 | 6.3 | 6.8 |
| hsa-miR-770-5p | 3.6 | 11.9 |
| hsa-miR-1226-5p | 3.6 | 10.2 |
| hsa-miR-1267 | 6.3 | 5.1 |
| hsa-miR-1306-3p | 6.3 | 5.1 |
| hsa-miR-3154 | 4.5 | 8.5 |
| hsa-miR-329 | 3.6 | 10.2 |
| hsa-miR-4659b-3p | 7.2 | 3.4 |
| hsa-miR-6134 | 3.6 | 10.2 |
| hsa-miR-181a-3p | 4.5 | 6.8 |
| hsa-miR-1827 | 5.4 | 5.1 |
| hsa-miR-3926 | 2.7 | 10.2 |
| hsa-miR-662 | 4.5 | 6.8 |
| hsa-miR-127-3p | 4.5 | 5.1 |
| hsa-miR-148a-5p | 3.6 | 6.8 |
| hsa-miR-18b-3p | 3.6 | 6.8 |
| hsa-miR-202-3p | 2.7 | 8.5 |
| hsa-miR-4325 | 2.7 | 8.5 |
| hsa-miR-4673 | 5.4 | 3.4 |
| hsa-miR-4730 | 6.3 | 1.7 |
| hsa-miR-489 | 4.5 | 5.1 |
| hsa-miR-584-3p | 4.5 | 5.1 |
| hsa-miR-6720-3p | 1.8 | 10.2 |
| hsa-let-7i-3p | 5.4 | 1.7 |
| hsa-miR-1307-5p | 3.6 | 5.1 |
| hsa-miR-204-5p | 4.5 | 3.4 |
| hsa-miR-218-5p | 4.5 | 3.4 |
| hsa-miR-378e | 3.6 | 5.1 |
| hsa-miR-3911 | 2.7 | 6.8 |
| hsa-miR-543 | 3.6 | 5.1 |
| hsa-miR-5703 | 3.6 | 5.1 |
| hsa-miR-589-3p | 3.6 | 5.1 |
| hsa-miR-885-5p | 1.8 | 8.5 |
| hsa-let-7g-3p | 3.6 | 3.4 |
| hsa-miR-1185-2-3p | 4.5 | 1.7 |
| hsa-miR-1238-5p | 3.6 | 3.4 |
| hsa-miR-19b-1-5p | 3.6 | 3.4 |
| hsa-miR-3130-5p | 2.7 | 5.1 |
| hsa-miR-3163 | 3.6 | 3.4 |
| hsa-miR-377-3p | 2.7 | 5.1 |
| hsa-miR-421 | 2.7 | 5.1 |
| hsa-miR-4419a | 2.7 | 5.1 |
| hsa-miR-4425 | 3.6 | 3.4 |
| hsa-miR-4470 | 3.6 | 3.4 |
| hsa-miR-4539 | 2.7 | 5.1 |
| hsa-miR-516a-5p | 3.6 | 3.4 |
| hsa-miR-610 | 4.5 | 1.7 |
| hsa-miR-628-5p | 3.6 | 3.4 |
| hsa-miR-99b-3p | 2.7 | 5.1 |
| hsa-let-7f-2-3p | 2.7 | 3.4 |
| hsa-miR-193a-3p | 0.9 | 6.8 |
| hsa-miR-195-3p | 2.7 | 3.4 |
| hsa-miR-221-5p | 3.6 | 1.7 |
| hsa-miR-223-5p | 4.5 | 0.0 |
| hsa-miR-23a-5p | 1.8 | 5.1 |
| hsa-miR-25-5p | 1.8 | 5.1 |
| hsa-miR-3616-3p | 0.9 | 6.8 |
| hsa-miR-376c-3p | 1.8 | 5.1 |
| hsa-miR-4701-3p | 2.7 | 3.4 |
| hsa-miR-4743-5p | 1.8 | 5.1 |
| hsa-miR-5008-5p | 1.8 | 5.1 |
| hsa-miR-570-3p | 2.7 | 3.4 |
| hsa-miR-595 | 1.8 | 5.1 |
| hsa-miR-6716-3p | 3.6 | 1.7 |
| hsa-miR-887 | 2.7 | 3.4 |
| hsa-miR-1299 | 0.9 | 5.1 |
| hsa-miR-133a | 2.7 | 1.7 |
| hsa-miR-198 | 1.8 | 3.4 |
| hsa-miR-3622b-5p | 0.9 | 5.1 |
| hsa-miR-373-5p | 3.6 | 0.0 |
| hsa-miR-3917 | 0.9 | 5.1 |
| hsa-miR-409-5p | 1.8 | 3.4 |
| hsa-miR-4440 | 2.7 | 1.7 |
| hsa-miR-4514 | 0.9 | 5.1 |
| hsa-miR-4535 | 0.9 | 5.1 |
| hsa-miR-4668-5p | 0.9 | 5.1 |
| hsa-miR-4776-5p | 0.9 | 5.1 |
| hsa-miR-4793-3p | 2.7 | 1.7 |
| hsa-miR-542-3p | 0.9 | 5.1 |
| hsa-miR-548am-5p | 1.8 | 3.4 |
| hsa-miR-548q | 1.8 | 3.4 |
| hsa-miR-582-5p | 2.7 | 1.7 |
| hsa-miR-654-5p | 1.8 | 3.4 |
| hsa-miR-758-3p | 2.7 | 1.7 |
| hsa-miR-760 | 0.0 | 6.8 |
| hsa-miR-765 | 1.8 | 3.4 |
| hsa-miR-875-5p | 1.8 | 3.4 |
| hsa-miR-106a-3p | 2.7 | 0.0 |
| hsa-miR-1236-3p | 0.0 | 5.1 |
| hsa-miR-1255b-5p | 1.8 | 1.7 |
| hsa-miR-181c-3p | 2.7 | 0.0 |
| hsa-miR-26a-2-3p | 0.9 | 3.4 |
| hsa-miR-298 | 0.9 | 3.4 |
| hsa-miR-3194-5p | 0.9 | 3.4 |
| hsa-miR-3620-3p | 1.8 | 1.7 |
| hsa-miR-374a-3p | 1.8 | 1.7 |
| hsa-miR-411-3p | 1.8 | 1.7 |
| hsa-miR-4475 | 0.9 | 3.4 |
| hsa-miR-4476 | 0.9 | 3.4 |
| hsa-miR-4716-5p | 1.8 | 1.7 |
| hsa-miR-4762-3p | 1.8 | 1.7 |
| hsa-miR-544a | 1.8 | 1.7 |
| hsa-miR-548d-5p | 1.8 | 1.7 |
| hsa-miR-561-3p | 1.8 | 1.7 |
| hsa-miR-5695 | 2.7 | 0.0 |
| hsa-miR-580 | 1.8 | 1.7 |
| hsa-miR-612 | 1.8 | 1.7 |
| hsa-miR-622 | 0.9 | 3.4 |
| hsa-miR-670 | 1.8 | 1.7 |
| hsa-miR-744-3p | 1.8 | 1.7 |
| hsa-let-7a-3p | 0.9 | 1.7 |
| hsa-miR-1255a | 0.9 | 1.7 |
| hsa-miR-1270 | 0.9 | 1.7 |
| hsa-miR-185-3p | 0.0 | 3.4 |
| hsa-miR-186-3p | 0.0 | 3.4 |
| hsa-miR-187-5p | 0.9 | 1.7 |
| hsa-miR-194-3p | 1.8 | 0.0 |
| hsa-miR-200b-5p | 0.9 | 1.7 |
| hsa-miR-2052 | 0.0 | 3.4 |
| hsa-miR-224-5p | 0.9 | 1.7 |
| hsa-miR-2964a-5p | 0.9 | 1.7 |
| hsa-miR-29b-1-5p | 0.9 | 1.7 |
| hsa-miR-30d-3p | 0.0 | 3.4 |
| hsa-miR-3150b-5p | 1.8 | 0.0 |
| hsa-miR-3184-3p | 0.9 | 1.7 |
| hsa-miR-32-3p | 0.9 | 1.7 |
| hsa-miR-323a-3p | 1.8 | 0.0 |
| hsa-miR-3663-5p | 1.8 | 0.0 |
| hsa-miR-370 | 0.9 | 1.7 |
| hsa-miR-376a-5p | 0.9 | 1.7 |
| hsa-miR-381-3p | 0.9 | 1.7 |
| hsa-miR-3924 | 0.0 | 3.4 |
| hsa-miR-3945 | 0.9 | 1.7 |
| hsa-miR-422a | 1.8 | 0.0 |
| hsa-miR-4289 | 0.9 | 1.7 |
| hsa-miR-432-3p | 0.0 | 3.4 |
| hsa-miR-4468 | 0.9 | 1.7 |
| hsa-miR-452-3p | 0.9 | 1.7 |
| hsa-miR-452-5p | 0.0 | 3.4 |
| hsa-miR-4714-5p | 0.9 | 1.7 |
| hsa-miR-504 | 1.8 | 0.0 |
| hsa-miR-5088 | 0.0 | 3.4 |
| hsa-miR-518b | 0.9 | 1.7 |
| hsa-miR-545-3p | 0.9 | 1.7 |
| hsa-miR-545-5p | 0.9 | 1.7 |
| hsa-miR-548at-5p | 0.9 | 1.7 |
| hsa-miR-556-3p | 0.9 | 1.7 |
| hsa-miR-559 | 0.0 | 3.4 |
| hsa-miR-5686 | 0.9 | 1.7 |
| hsa-miR-5692a | 0.0 | 3.4 |
| hsa-miR-586 | 0.9 | 1.7 |
| hsa-miR-590-3p | 1.8 | 0.0 |
| hsa-miR-601 | 0.9 | 1.7 |
| hsa-miR-607 | 0.9 | 1.7 |
| hsa-miR-619 | 0.0 | 3.4 |
| hsa-miR-624-3p | 1.8 | 0.0 |
| hsa-miR-642a-5p | 0.9 | 1.7 |
| hsa-miR-645 | 0.9 | 1.7 |
| hsa-miR-668 | 0.9 | 1.7 |
| hsa-miR-6722-3p | 1.8 | 0.0 |
| hsa-miR-675-5p | 0.9 | 1.7 |
| hsa-miR-888-3p | 0.9 | 1.7 |
| hsa-miR-937-3p | 0.9 | 1.7 |
| hsa-miR-939-3p | 0.9 | 1.7 |
| hsa-miR-10b-3p | 0.0 | 1.7 |
| hsa-miR-10b-5p | 0.0 | 1.7 |
| hsa-miR-1183 | 0.0 | 1.7 |
| hsa-miR-1208 | 0.0 | 1.7 |
| hsa-miR-1226-3p | 0.0 | 1.7 |
| hsa-miR-1228-5p | 0.0 | 1.7 |
| hsa-miR-124-3p | 0.9 | 0.0 |
| hsa-miR-124-5p | 0.0 | 1.7 |
| hsa-miR-1247-3p | 0.9 | 0.0 |
| hsa-miR-1261 | 0.0 | 1.7 |
| hsa-miR-1269a | 0.0 | 1.7 |
| hsa-miR-1273d | 0.9 | 0.0 |
| hsa-miR-1285-5p | 0.0 | 1.7 |
| hsa-miR-1287 | 0.0 | 1.7 |
| hsa-miR-1296 | 0.0 | 1.7 |
| hsa-miR-143-3p | 0.9 | 0.0 |
| hsa-miR-1538 | 0.0 | 1.7 |
| hsa-miR-16-1-3p | 0.9 | 0.0 |
| hsa-miR-184 | 0.9 | 0.0 |
| hsa-miR-188-3p | 0.9 | 0.0 |
| hsa-miR-1909-5p | 0.0 | 1.7 |
| hsa-miR-1910 | 0.0 | 1.7 |
| hsa-miR-196a-3p | 0.9 | 0.0 |
| hsa-miR-19a-5p | 0.0 | 1.7 |
| hsa-miR-19b-2-5p | 0.9 | 0.0 |
| hsa-miR-205-5p | 0.9 | 0.0 |
| hsa-miR-206 | 0.0 | 1.7 |
| hsa-miR-20b-3p | 0.9 | 0.0 |
| hsa-miR-2115-5p | 0.9 | 0.0 |
| hsa-miR-218-1-3p | 0.0 | 1.7 |
| hsa-miR-218-2-3p | 0.9 | 0.0 |
| hsa-miR-2277-3p | 0.0 | 1.7 |
| hsa-miR-2681-3p | 0.9 | 0.0 |
| hsa-miR-26a-1-3p | 0.9 | 0.0 |
| hsa-miR-27b-5p | 0.0 | 1.7 |
| hsa-miR-297 | 0.0 | 1.7 |
| hsa-miR-29a-5p | 0.0 | 1.7 |
| hsa-miR-300 | 0.9 | 0.0 |
| hsa-miR-301b | 0.9 | 0.0 |
| hsa-miR-302b-3p | 0.0 | 1.7 |
| hsa-miR-30a-3p | 0.9 | 0.0 |
| hsa-miR-3132 | 0.0 | 1.7 |
| hsa-miR-3149 | 0.0 | 1.7 |
| hsa-miR-3157-5p | 0.0 | 1.7 |
| hsa-miR-3161 | 0.0 | 1.7 |
| hsa-miR-32-5p | 0.9 | 0.0 |
| hsa-miR-330-5p | 0.9 | 0.0 |
| hsa-miR-33a-3p | 0.9 | 0.0 |
| hsa-miR-33b-5p | 0.0 | 1.7 |
| hsa-miR-34c-3p | 0.0 | 1.7 |
| hsa-miR-3591-3p | 0.0 | 1.7 |
| hsa-miR-3607-3p | 0.9 | 0.0 |
| hsa-miR-3654 | 0.0 | 1.7 |
| hsa-miR-3666 | 0.0 | 1.7 |
| hsa-miR-367-5p | 0.9 | 0.0 |
| hsa-miR-374b-3p | 0.9 | 0.0 |
| hsa-miR-379-3p | 0.9 | 0.0 |
| hsa-miR-380-5p | 0.9 | 0.0 |
| hsa-miR-3935 | 0.0 | 1.7 |
| hsa-miR-3937 | 0.0 | 1.7 |
| hsa-miR-3942-3p | 0.9 | 0.0 |
| hsa-miR-3976 | 0.0 | 1.7 |
| hsa-miR-410 | 0.0 | 1.7 |
| hsa-miR-4259 | 0.0 | 1.7 |
| hsa-miR-4272 | 0.0 | 1.7 |
| hsa-miR-4290 | 0.0 | 1.7 |
| hsa-miR-4294 | 0.0 | 1.7 |
| hsa-miR-431-5p | 0.0 | 1.7 |
| hsa-miR-4420 | 0.9 | 0.0 |
| hsa-miR-4422 | 0.0 | 1.7 |
| hsa-miR-4489 | 0.0 | 1.7 |
| hsa-miR-4500 | 0.9 | 0.0 |
| hsa-miR-450a-5p | 0.9 | 0.0 |
| hsa-miR-450b-3p | 0.0 | 1.7 |
| hsa-miR-451b | 0.9 | 0.0 |
| hsa-miR-4520b-3p | 0.0 | 1.7 |
| hsa-miR-4639-3p | 0.9 | 0.0 |
| hsa-miR-4648 | 0.0 | 1.7 |
| hsa-miR-4657 | 0.0 | 1.7 |
| hsa-miR-4677-3p | 0.9 | 0.0 |
| hsa-miR-4677-5p | 0.9 | 0.0 |
| hsa-miR-4685-3p | 0.9 | 0.0 |
| hsa-miR-4694-3p | 0.0 | 1.7 |
| hsa-miR-4695-3p | 0.0 | 1.7 |
| hsa-miR-4707-5p | 0.0 | 1.7 |
| hsa-miR-4710 | 0.0 | 1.7 |
| hsa-miR-4723-3p | 0.9 | 0.0 |
| hsa-miR-4726-5p | 0.0 | 1.7 |
| hsa-miR-4733-3p | 0.0 | 1.7 |
| hsa-miR-4733-5p | 0.9 | 0.0 |
| hsa-miR-4736 | 0.0 | 1.7 |
| hsa-miR-4740-5p | 0.0 | 1.7 |
| hsa-miR-4755-3p | 0.0 | 1.7 |
| hsa-miR-4762-5p | 0.0 | 1.7 |
| hsa-miR-4763-5p | 0.0 | 1.7 |
| hsa-miR-4785 | 0.0 | 1.7 |
| hsa-miR-4792 | 0.9 | 0.0 |
| hsa-miR-4800-3p | 0.9 | 0.0 |
| hsa-miR-493-5p | 0.0 | 1.7 |
| hsa-miR-5007-3p | 0.9 | 0.0 |
| hsa-miR-5011-5p | 0.9 | 0.0 |
| hsa-miR-5087 | 0.0 | 1.7 |
| hsa-miR-5093 | 0.0 | 1.7 |
| hsa-miR-513a-3p | 0.0 | 1.7 |
| hsa-miR-513c-3p | 0.0 | 1.7 |
| hsa-miR-517c-3p | 0.0 | 1.7 |
| hsa-miR-518a-5p | 0.0 | 1.7 |
| hsa-miR-5196-3p | 0.9 | 0.0 |
| hsa-miR-520c-3p | 0.9 | 0.0 |
| hsa-miR-541-3p | 0.0 | 1.7 |
| hsa-miR-548a-3p | 0.9 | 0.0 |
| hsa-miR-548ap-3p | 0.9 | 0.0 |
| hsa-miR-548d-3p | 0.9 | 0.0 |
| hsa-miR-548e | 0.9 | 0.0 |
| hsa-miR-552 | 0.9 | 0.0 |
| hsa-miR-558 | 0.0 | 1.7 |
| hsa-miR-5591-3p | 0.0 | 1.7 |
| hsa-miR-5681b | 0.9 | 0.0 |
| hsa-miR-5692b | 0.9 | 0.0 |
| hsa-miR-5692c | 0.9 | 0.0 |
| hsa-miR-571 | 0.0 | 1.7 |
| hsa-miR-588 | 0.9 | 0.0 |
| hsa-miR-589-5p | 0.9 | 0.0 |
| hsa-miR-593-3p | 0.9 | 0.0 |
| hsa-miR-597 | 0.0 | 1.7 |
| hsa-miR-609 | 0.9 | 0.0 |
| hsa-miR-615-3p | 0.0 | 1.7 |
| hsa-miR-615-5p | 0.0 | 1.7 |
| hsa-miR-616-5p | 0.9 | 0.0 |
| hsa-miR-618 | 0.0 | 1.7 |
| hsa-miR-621 | 0.9 | 0.0 |
| hsa-miR-631 | 0.0 | 1.7 |
| hsa-miR-633 | 0.0 | 1.7 |
| hsa-miR-637 | 0.0 | 1.7 |
| hsa-miR-639 | 0.9 | 0.0 |
| hsa-miR-642b-5p | 0.9 | 0.0 |
| hsa-miR-646 | 0.9 | 0.0 |
| hsa-miR-6509-3p | 0.9 | 0.0 |
| hsa-miR-651 | 0.9 | 0.0 |
| hsa-miR-6511a-3p | 0.0 | 1.7 |
| hsa-miR-657 | 0.9 | 0.0 |
| hsa-miR-6722-5p | 0.0 | 1.7 |
| hsa-miR-708-5p | 0.9 | 0.0 |
| hsa-miR-767-5p | 0.9 | 0.0 |
| hsa-miR-875-3p | 0.0 | 1.7 |
| hsa-miR-876-5p | 0.9 | 0.0 |
| hsa-miR-877-5p | 0.9 | 0.0 |
| hsa-miR-891a | 0.9 | 0.0 |
| hsa-miR-920 | 0.9 | 0.0 |
| hsa-miR-922 | 0.9 | 0.0 |
| hsa-miR-924 | 0.0 | 1.7 |
| hsa-miR-92a-2-5p | 0.9 | 0.0 |
| hsa-miR-935 | 0.9 | 0.0 |
| hsa-miR-938 | 0.0 | 1.7 |
| hsa-miR-943 | 0.9 | 0.0 |
| hsa-miR-423-5p | 100.0 | 100.0 |
FACT-Hep consists of 27-item FACT-G, and 18-item Hepatobiliary Subscale. FACT-Hep questionnaire uses 5-point Likert rating scale, range '0'-not at all to '4'. FACT-Hep total score ranges from 0 to 180, where highest score represents maximum achievable quality of life. Domains of FACT-G include Physical Well-Being (PWB), Social/Family Well-Being (SWB), Emotional Well-Being (EWB) and Functional Well-Being (FWB). Hepatobiliary disease specific items include: swelling or cramps, losing weight, gastrointestinal (GI)-related questions, lack of energy, side effects, pain, fatigue, usual activities, jaundice, fevers, itching, taste of food and chills. Eight of the items (pain, back pain, stomach pain/discomfort, lack of energy, fatigue, nausea, weight loss and jaundice) make up FACT-Hepatobiliary Symptom Index (FHSI-8), and are considered to be symptoms specific to hepatobiliary cancer. Table below included mixed effect model estimated average based on all observed values/time points.
| units on a scale | Axitinib | Placebo |
|---|---|---|
| Functional Assessment of Cancer Therapy - Hepatobiliary Questionnaire (FACT-Hep) in Randomized Portion: Overall Between-Treatment Comparison Based on the Repeated Measures Mixed Effects Model | 123.33 (120.17 to 126.50) | 135.22 (129.17 to 141.27) |
FACT-G is core questionnaire of Functional Assessment of Chronic Illness Therapy (FACIT) measurement system to evaluate QoL in cancer population. FACT-G consisted of 27 questions grouped in 4 domains of general Health-Related QoL (HRQoL): PWB, SWB, EWB and FWB; each ranging from 0 (not at all) to 4 (very much). FACT-G ranged between 0 and 108. Since questions could be reversed coded, as appropriate, before calculating FACT-G, 0 and 108 could be considered worst and best health states. The below table included the model estimated average based on all the observed values/time points. The mixed effect model was used.
| units on a scale | Axitinib | Placebo |
|---|---|---|
| Functional Assessment of Cancer Therapy - General (FACT-G) in Randomized Portion: Overall Between-Treatment Comparison Based on the Repeated Measures Mixed Effects Model | 71.20 (69.00 to 73.41) | 78.81 (74.68 to 82.93) |
The FACT-Hep includes the FACT-G and a hepatobiliary module. The hepatobiliary disease specific items include: swelling or cramps, losing weight, GI related questions, lack of energy, side effects, pain, fatigue, usual activities, jaundice, fevers, itching, taste of food and chills. Eight of the items (pain, back pain, stomach pain/discomfort, lack of energy, fatigue, nausea, weight loss, and jaundice) make up the FHSI-8, and are considered to be symptoms specific to hepatobiliary cancer. FHSI-8 total score ranges from 0 to 32 where "0" is a severely symptomatic participant and the highest score indicates an asymptomatic participant. The below table included the model estimated average based on all the observed values/time points. The mixed effect model was used.
| units on a scale | Axitinib | Placebo |
|---|---|---|
| Functional Assessment of Cancer Therapy (FACT)-Hepatobiliary Symptom Index-8 (FHSI-8) in Randomized Portion: Overall Between-Treatment Comparison Based on the Repeated Measures Mixed Effects Model | 23.42 (22.77 to 24.07) | 26.69 (25.35 to 28.03) |
FACT-G is core questionnaire of Functional Assessment of Chronic Illness Therapy (FACIT) measurement system to evaluate QoL in cancer population. FACT-G consisted of 27 questions grouped in 4 domains of general HRQoL: PWB, SWB, EWB and FWB. Each of the individual subscale, except EWB has 7 items and each integer scored 0 to 4 making a maximum possible score of 28 (range 0 to 28). EWB has 6 items and each integer scored 0 to 4 making a maximum possible score of 24 (range 0 to 24). For all the 4 scales, higher values correspond to better health. The below table included the model estimated average based on all the observed values/time points. The mixed effect model was used.
| units on a scale | Axitinib | Placebo |
|---|---|---|
| PWB | 19.39 (18.72 to 20.07) | 23.13 (21.76 to 24.50) |
| SWB | 18.94 (18.05 to 19.83) | 20.21 (18.66 to 21.77) |
| EWB | 17.23 (16.63 to 17.84) | 17.71 (16.54 to 18.89) |
| FWB | 15.76 (14.88 to 16.65) | 17.83 (16.19 to 19.47) |
This subscale consists of 18 items rated on a scale from '0' - not at all to '4' - very much regarding how much each item was present in the last 7 days. FACT-Hep-CS18 total score ranges from 0 to 72. The higher score reflects better QoL or fewer symptoms. The 18 items of this scale are associated with hepatocellular carcinoma. The below table included the model estimated average based on all the observed values/time points. The mixed effect model was used.
| units on a scale | Axitinib | Placebo |
|---|---|---|
| Functional Assessment of Cancer Therapy - Hepatobiliary Cancer Subscale (FACT Hep-CS18) Questionnaire in Randomized Portion: Overall Between-Treatment Comparison Based on the Repeated Measures Mixed Effects Model | 51.78 (50.46 to 53.10) | 56.74 (54.08 to 59.39) |
The trial outcome index is defined to be the sum (PWB+FWB+HepCS), making it 32 items altogether. Each ranges from '0' - not at all to '4' - very much regarding how much each item was present in the last 7 days. FACT Hep -TOI total score ranges from 0 to 128, where the highest score represents a maximum achievable quality of life. The below table included the model estimated average based on all the observed values/time points. The mixed effect model was used.
| units on a scale | Axitinib | Placebo |
|---|---|---|
| Functional Assessment of Cancer Therapy - Hepatobiliary Cancer Trial Outcome Index (FACT Hep-TOI) Questionnaire in Randomized Portion: Overall Between-Treatment Comparison Based on the Repeated Measures Mixed Effects Model | 87.28 (84.98 to 89.58) | 97.73 (93.24 to 102.23) |
TTD analysis was performed for FHSI-8. Time to deterioration was defined as the time between date of randomization and date of the event.
| months | Axitinib | Placebo |
|---|---|---|
| Time to Deterioration (TTD) Based on the Composite Endpoint in Randomized Portion: Overall Between-Treatment Comparison Based on the Repeated Measures Mixed Effects Model | 1.9 (1.8 to 1.9) | 1.9 (1.8 to 2.7) |
EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state. Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state. The below table included the model estimated average based on all the observed values/time points. The mixed effect model was used.
| units on a scale | Axitinib | Placebo |
|---|---|---|
| EuroQoL (EQ-5D)- Health State Profile Utility Score in Randomized Portion: Overall Between-Treatment Comparison Based on the Repeated Measures Mixed Effects Model | 0.67 (0.63 to 0.70) | 0.79 (0.72 to 0.86) |
EQ-5D VAS in rates the participant's overall health status using values from 0 (worst imaginable) to 100 (best imaginable). The below table included the model estimated average based on all the observed values/time points. The mixed effect model was used.
| units on a scale | Axitinib | Placebo |
|---|---|---|
| EuroQoL Visual Analogue Scale (EQ-VAS) in Randomized Portion: Overall Between-Treatment Comparison Based on the Repeated Measures Mixed Effects Model | 68.67 (66.11 to 71.23) | 75.70 (70.40 to 81.00) |
Number of Child-Pugh Class B (score 7) participants with DLT was evaluated during Cycle 1 of treatment in the non-randomized portion of the study.
| participants | Child-Pugh Class A | Child-Pugh Class B |
|---|---|---|
| Number of Participants With Dose-Limiting Toxicities (DLTs) in Non-Randomized Portion | — | 2 |
An AE was an untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. Serious adverse event (SAE) was an AE resulting in any of the following outcomes: death, initial or prolonged inpatient hospitalization, life-threatening experience, persistent or significant disability/incapacity, congenital anomaly. Treatment-emergent AEs were those with initial onset or that worsen in severity after the first dose of study medication. The grade of an AE was determined according to Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0.
| participants | Child-Pugh Class A | Child-Pugh Class B |
|---|---|---|
| Participants with AEs | 15 | 7 |
| Participants with SAEs | 10 | 3 |
| Participants >=Grade 3 AEs | 13 | 5 |
| Participants Grade 5 AEs | 4 | 1 |
Treatment-related AE was any untoward medical occurrence in a participant with causal relationship to the study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. The grade of an AE was determined according to CTCAE Version 3.0.
| participants | Child-Pugh Class A | Child-Pugh Class B |
|---|---|---|
| Participants with AEs | 14 ± 3.55 | 6 ± 2.42 |
| Participants with SAEs | 2 | 2 |
| Participants ≥Grade 3 AEs | 9 | 4 |
| Participants Grade 5 AEs | 0 | 0 |
An AE was an untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes: death, initial or prolonged inpatient hospitalization, life-threatening experience, persistent or significant disability/incapacity, congenital anomaly. Treatment-emergent AEs were those with initial onset or that worsen in severity after the first dose of study medication. The grade of an AE was determined according to CTCAE Version 3.0.
| participants | Axitinib | Placebo |
|---|---|---|
| Participants with AEs | 131 | 63 |
| Participants with SAEs | 62 | 16 |
| Participants with Grade >=3 AEs | 109 | 26 |
| Participants with Grade 5 AEs | 16 | 8 |
Treatment-related AE was any untoward medical occurrence in a participant with causal relationship to the study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. The grade of an AE was determined according to CTCAE Version 3.0.
| participants | Axitinib | Placebo |
|---|---|---|
| Participants with AEs | 128 | 40 |
| Participants with SAEs | 24 | 1 |
| Participants with Grade >=3 AEs | 90 | 12 |
| Participants with Grade 5 AEs | 1 | 0 |
Collected over Baseline up to follow-up visit (up to 6 years). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Child-Pugh Class A | — | 10/15 (66.7%) | 15/15 (100%) |
| Child-Pugh Class B | — | 3/7 (42.9%) | 7/7 (100%) |
| Axitinib | — | 62/133 (46.6%) | 130/133 (97.7%) |
| Placebo | — | 16/68 (23.5%) | 55/68 (80.9%) |
| Event | Child-Pugh Class A | Child-Pugh Class B | Axitinib | Placebo |
|---|---|---|---|---|
| Disease progressionGeneral disorders | 3/15 | 0/7 | 8/133 | 4/68 |
| Varices oesophagealGastrointestinal disorders | 0/15 | 1/7 | 0/133 | 0/68 |
| Peritonitis bacterialInfections and infestations | 0/15 | 1/7 | 0/133 | 0/68 |
| Electrolyte imbalanceMetabolism and nutrition disorders | 0/15 | 1/7 | 0/133 | 0/68 |
| HyponatraemiaMetabolism and nutrition disorders | 0/15 | 1/7 | 0/133 | 0/68 |
| Hepatocellular carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/15 | 1/7 | 1/133 | 0/68 |
| EncephalopathyNervous system disorders | 0/15 | 1/7 | 2/133 | 0/68 |
| Cholecystitis acuteHepatobiliary disorders | 2/15 | 0/7 | 1/133 | 0/68 |
| Abdominal painGastrointestinal disorders | 1/15 | 0/7 | 3/133 | 2/68 |
| Enterocolitis haemorrhagicGastrointestinal disorders | 1/15 | 0/7 | 0/133 | 0/68 |
| Event | Child-Pugh Class A | Child-Pugh Class B | Axitinib | Placebo |
|---|---|---|---|---|
| FatigueGeneral disorders | 12/15 | 2/7 | 46/133 | 18/68 |
| Decreased appetiteMetabolism and nutrition disorders | 6/15 | 5/7 | 62/133 | 14/68 |
| DiarrhoeaGastrointestinal disorders | 9/15 | 1/7 | 71/133 | 8/68 |
| HypertensionVascular disorders | 7/15 | 3/7 | 72/133 | 9/68 |
| Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders | 8/15 | 2/7 | 45/133 | 4/68 |
| NauseaGastrointestinal disorders | 5/15 | 3/7 | 35/133 | 7/68 |
| Weight decreasedInvestigations | 5/15 | 3/7 | 36/133 | 2/68 |
| HyponatraemiaMetabolism and nutrition disorders | 1/15 | 3/7 | 8/133 | 3/68 |
| DysphoniaRespiratory, thoracic and mediastinal disorders | 6/15 | 3/7 | 33/133 | 0/68 |
| Abdominal painGastrointestinal disorders | 6/15 | 1/7 | 45/133 | 12/68 |
Full analysis set (FAS) included all randomized participants, and participants were classified according to the randomized treatment arm regardless of what treatment, if any, was received.
| Age, Customized(Participants) | Child-Pugh Class A | Child-Pugh Class B | Axitinib | Placebo | Total |
|---|---|---|---|---|---|
| <18 years | 0 | 0 | 0 | 0 | 0 |
| 18-44 years | 4 | 0 | 7 | 4 | 15 |
| 45-64 years | 5 | 5 | 74 | 32 | 116 |
| >=65 years | 6 | 2 | 53 | 32 | 93 |
| Sex: Female, Male(Participants) | Child-Pugh Class A | Child-Pugh Class B | Axitinib | Placebo | Total |
|---|---|---|---|---|---|
| Female | 3 | 2 | 24 | 12 | 41 |
| Male | 12 | 5 | 110 | 56 | 183 |
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Dec 2010 to primary completion in Mar 2014, 38 months.
Results were first posted in May 2015, 1 year 2 months after primary completion. A results delay was requested in Mar 2014.
Of 80 industry-sponsored phase 2 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 50. This study's 38 months is close to that.
Counting every sponsor, half of 428 studies reached it within 43 months; a quarter within 30 and three quarters within 71.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Axitinib